Vertex's CF Three-Drug Combo Excels In Phase III, But Filing Depends On Second Regimen's Results

 
• By Joseph Haas

Vertex duplicated promising efficacy observed in Phase II for its cystic fibrosis triple combo that includes VX-659, but wants to see data expected in early 2019 for a triplet containing VX-445 before filing for approvals.

Cystic Fibrosis, Medical Concept with Pills, Injections and Syringe. Cystic Fibrosis - Printed Diagnosis with Blurred Text. 3D Render.

More from Clinical Trials

More from R&D